Novartis Acquires Regulus Therapeutics, Expanding its RNA-Based Drug Pipeline
The Pharma Data
JUNE 25, 2025
Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.
Let's personalize your content